Acumen Pharmaceuticals Inc

NASDAQ ABOS

Download Data

Acumen Pharmaceuticals Inc EBIT to Total Assets Ratio 5 year CAGR for the quarter ending March 31, 2024

Acumen Pharmaceuticals Inc EBIT to Total Assets Ratio 5 year CAGR is NA for the quarter ending March 31, 2024. The EBIT to Total Assets Ratio measures a company's operating earnings (EBIT) generated per dollar of total assets. It shows how efficiently a company utilizes its assets to generate earnings. A higher ratio indicates better asset utilization and profitability. It reflects the ability of a company to generate earnings from its invested assets and is useful in assessing operational efficiency and financial performance. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Acumen Pharmaceuticals Inc EBIT to Total Assets Ratio for the quarter ending March 31, 2023 was -0.07, a -67.15% change year over year.
  • Acumen Pharmaceuticals Inc EBIT to Total Assets Ratio for the quarter ending March 31, 2022 was -0.04, a -104.16% change year over year.
  • Acumen Pharmaceuticals Inc EBIT to Total Assets Ratio for the quarter ending March 31, 2021 was 1.01.
NASDAQ: ABOS

Acumen Pharmaceuticals Inc

CEO Mr. Daniel J. O'Connell M.B.A.
IPO Date July 1, 2021
Location United States
Headquarters 427 Park Street, Charlottesville, VA, United States, 22902
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email